618 related articles for article (PubMed ID: 30149462)
1. Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells.
Li H; Jiang H; Zhang B; Feng J
J Parkinsons Dis; 2018; 8(4):479-493. PubMed ID: 30149462
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease in a dish - Using stem cells as a molecular tool.
Badger JL; Cordero-Llana O; Hartfield EM; Wade-Martins R
Neuropharmacology; 2014 Jan; 76 Pt A():88-96. PubMed ID: 24035919
[TBL] [Abstract][Full Text] [Related]
3. Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease.
Beevers JE; Caffrey TM; Wade-Martins R
Biochem Soc Trans; 2013 Dec; 41(6):1503-8. PubMed ID: 24256244
[TBL] [Abstract][Full Text] [Related]
4. Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation.
Chung SY; Kishinevsky S; Mazzulli JR; Graziotto J; Mrejeru A; Mosharov EV; Puspita L; Valiulahi P; Sulzer D; Milner TA; Taldone T; Krainc D; Studer L; Shim JW
Stem Cell Reports; 2016 Oct; 7(4):664-677. PubMed ID: 27641647
[TBL] [Abstract][Full Text] [Related]
5. Modeling Parkinson's disease using induced pluripotent stem cells.
Byers B; Lee HL; Reijo Pera R
Curr Neurol Neurosci Rep; 2012 Jun; 12(3):237-42. PubMed ID: 22538490
[TBL] [Abstract][Full Text] [Related]
6. Parkin Maintains Robust Pacemaking in Human Induced Pluripotent Stem Cell-Derived A9 Dopaminergic Neurons.
Pu J; Lin L; Jiang H; Hu Z; Li H; Yan Z; Zhang B; Feng J
Mov Disord; 2023 Jul; 38(7):1273-1281. PubMed ID: 37166002
[TBL] [Abstract][Full Text] [Related]
7. Induced pluripotent stem cells: a tool for modeling Parkinson's disease.
Bose A; Petsko GA; Studer L
Trends Neurosci; 2022 Aug; 45(8):608-620. PubMed ID: 35667922
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson's disease-like motor dysfunction.
Suda Y; Kuzumaki N; Sone T; Narita M; Tanaka K; Hamada Y; Iwasawa C; Shibasaki M; Maekawa A; Matsuo M; Akamatsu W; Hattori N; Okano H; Narita M
Mol Brain; 2018 Feb; 11(1):6. PubMed ID: 29458391
[TBL] [Abstract][Full Text] [Related]
9. Molecular chaperones and Parkinson's disease.
Hu S; Tan J; Qin L; Lv L; Yan W; Zhang H; Tang B; Wang C
Neurobiol Dis; 2021 Dec; 160():105527. PubMed ID: 34626793
[TBL] [Abstract][Full Text] [Related]
10. [Modeling Familial Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells].
Tabata Y; Okano H
Brain Nerve; 2019 Aug; 71(8):875-883. PubMed ID: 31346144
[TBL] [Abstract][Full Text] [Related]
11. Demonstration of brain region-specific neuronal vulnerability in human iPSC-based model of familial Parkinson's disease.
Brazdis RM; Alecu JE; Marsch D; Dahms A; Simmnacher K; Lörentz S; Brendler A; Schneider Y; Marxreiter F; Roybon L; Winner B; Xiang W; Prots I
Hum Mol Genet; 2020 May; 29(7):1180-1191. PubMed ID: 32160287
[TBL] [Abstract][Full Text] [Related]
12. Modeling Parkinson's disease with induced pluripotent stem cells harboring α-synuclein mutations.
Singh Dolt K; Hammachi F; Kunath T
Brain Pathol; 2017 Jul; 27(4):545-551. PubMed ID: 28585381
[TBL] [Abstract][Full Text] [Related]
13. Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells.
Jiang H; Ren Y; Yuen EY; Zhong P; Ghaedi M; Hu Z; Azabdaftari G; Nakaso K; Yan Z; Feng J
Nat Commun; 2012 Feb; 3():668. PubMed ID: 22314364
[TBL] [Abstract][Full Text] [Related]
14. Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes.
Sison SL; Vermilyea SC; Emborg ME; Ebert AD
Curr Neurol Neurosci Rep; 2018 Oct; 18(12):84. PubMed ID: 30284665
[TBL] [Abstract][Full Text] [Related]
15. Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson's Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology.
Diao X; Wang F; Becerra-Calixto A; Soto C; Mukherjee A
Cells; 2021 Sep; 10(9):. PubMed ID: 34572052
[TBL] [Abstract][Full Text] [Related]
16. Decoding Parkinson's disease - iPSC-derived models in the OMICs era.
Krach F; Bogiongko ME; Winner B
Mol Cell Neurosci; 2020 Jul; 106():103501. PubMed ID: 32439399
[TBL] [Abstract][Full Text] [Related]
17. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress.
Byers B; Cord B; Nguyen HN; Schüle B; Fenno L; Lee PC; Deisseroth K; Langston JW; Pera RR; Palmer TD
PLoS One; 2011; 6(11):e26159. PubMed ID: 22110584
[TBL] [Abstract][Full Text] [Related]
18. The role of alpha-synuclein in the development of the dopaminergic neurons in the substantia nigra and ventral tegmental area.
Tarasova TV; Lytkina OA; Roman AY; Bachurin SO; Ustyugov AA
Dokl Biol Sci; 2016; 466():5-7. PubMed ID: 27021360
[TBL] [Abstract][Full Text] [Related]
19. What we can learn from iPSC-derived cellular models of Parkinson's disease.
Caiazza MC; Lang C; Wade-Martins R
Prog Brain Res; 2020; 252():3-25. PubMed ID: 32247368
[TBL] [Abstract][Full Text] [Related]
20. Generation of Naivetropic Induced Pluripotent Stem Cells from Parkinson's Disease Patients for High-Efficiency Genetic Manipulation and Disease Modeling.
Hu Z; Pu J; Jiang H; Zhong P; Qiu J; Li F; Wang X; Zhang B; Yan Z; Feng J
Stem Cells Dev; 2015 Nov; 24(21):2591-604. PubMed ID: 26218671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
